Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VG801 in Stargardt Disease
NCT07002398Phase 2Recruiting
- Sponsor
- VeonGen Therapeutics
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, Engineered AAV
- Countries
- 1
01
Overview
A Phase 2 trial of VG801 in Stargardt disease (STGD), sponsored by VeonGen Therapeutics. Started Dec 2024; status: recruiting.
02
Drugs
VG801
03
Conditions
Stargardt disease (STGD)
Beyond the preview
Go deeper on NCT07002398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07002398.